Yuhan Corporation

Immuneoncia Therapeutics successfully raised ₩33.9 billion (US$24 million) in its Kosdaq IPO on May 19, with shares closing 108% higher than the offering price.

HLB Group announced plans to resubmit its targeted anticancer drug riboceranib for FDA approval by May after receiving a second rejection due to manufacturing issues with partner Hangseo Pharmaceutical.

Yuhan Corporation's third-generation EGFR-TKI lazertinib (Leclaza) has received European Commission approval in combination with J&J's Rybrevant for first-line treatment of EGFR-mutated non-small cell lung cancer.

Yuhan Corporation's Leclaza (lazertinib), a third-generation EGFR tyrosine kinase inhibitor, has received FDA approval for treating non-small cell lung cancer, becoming the first homegrown Korean anticancer drug to enter the US market. The drug has shown superior efficacy compared to competitor Tagrisso and demonstrates promising results in combination therapy with J&J's Rybrevant.

The urticaria treatment landscape is evolving, with over 20 companies developing more than 25 novel therapies to address unmet patient needs.

Leclaza (lazertinib) monotherapy demonstrated a progression-free survival (PFS) of 18.5 months, surpassing Tagrisso's (osimertinib) 16.6 months in EGFR-mutated NSCLC.

The FDA has approved lazertinib (LECLAZA) in combination with amivantamab (RYBREVANT) as a first-line treatment for NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.